Pear Therapeutic a Aktie [WKN DE: A3C80D / ISIN: US7047231052]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Pear Therapeutics Inc Registered Shs -A-

07.04.23		Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process (Businesswire)
17.03.23		Pear Therapeutics Exploring Strategic Alternatives To Maximize Shareholder Value (RTTNews)
17.03.23		Pear Therapeutics Announces Process Exploring Strategic Alternatives (Businesswire)
27.02.23		Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference (Businesswire)
02.02.23		Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Businesswire)
26.01.23		Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders (Businesswire)
18.01.23		Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List (Businesswire)
12.01.23		California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program (Businesswire)
10.01.23		Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics (Businesswire)
04.01.23		Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States (Businesswire)
15.12.22		Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP (Businesswire)
21.11.22		Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference (Businesswire)
14.11.22		Pear Therapeutics Reports Third Quarter 2022 Results (Businesswire)
10.11.22		Pear Therapeutics to Participate in the BTIG Digital Health Forum (Businesswire)
07.11.22		Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe (Businesswire)
03.11.22		State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis (Businesswire)
01.11.22		Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (Businesswire)
31.10.22		Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022 (Businesswire)
24.10.22		Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET® (Businesswire)
13.09.22		Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium (Businesswire)
07.09.22		Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Businesswire)
01.09.22		South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders (Businesswire)
31.08.22		Pear Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference (Businesswire)
11.08.22		Pear Therapeutics Reports Second Quarter 2022 Results (Businesswire)
10.08.22		Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® (Businesswire)
08.08.22		Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder (Businesswire)
03.08.22		Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder (Businesswire)
02.08.22		Pear Therapeutics to be Added to Russell US Index Series (Businesswire)
28.07.22		Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022 (Businesswire)
16.06.22		Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference (Businesswire)
15.06.22		Pear Therapeutics Announces Three New Board Members (Businesswire)
14.06.22		Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O® (Businesswire)
08.06.22		Pear Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst® at SLEEP 2022 (Businesswire)
06.06.22		Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months (Businesswire)
02.06.22		Pear Therapeutics to Participate in the Jefferies Healthcare Conference (Businesswire)
24.05.22		Pear Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting (Businesswire)
19.05.22		Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 (Businesswire)
16.05.22		Pear Therapeutics Reports First Quarter 2022 Financial Results (Businesswire)
12.05.22		Pear Therapeutics Announces the Inclusion of QuickMD in Its Telehealth Provider Experience Initiative (Businesswire)
11.05.22		Pear Therapeutics to Participate in the 17th Annual Needham Technology & Media Conference (Businesswire)
03.05.22		Pear Therapeutics to Participate in the Bank of America 2022 Healthcare Conference (Businesswire)
02.05.22		Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022 (Businesswire)
18.04.22		Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit (Businesswire)
13.04.22		Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain (Businesswire)
05.04.22		Pear Therapeutics to Participate in Upcoming Investor Conferences (Businesswire)
04.04.22		Pear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery Through a Telehealth Provider Experience (Businesswire)
31.03.22		Pear Therapeutics to Participate in Upcoming Investor Event Hosted by Credit Suisse (Businesswire)
28.03.22		Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
25.03.22		Pre-market Movers: CLVR, JWEL, HNST, CVM, AMPS… (RTTNews)
24.03.22		Pear Therapeutics Joins Epic App Orchard to Enable Clinicians to Monitor Prescription Digital Therapeutics (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin bald bei 100.000 Dollar? MicroStrategy-CEO zeigt sich bullish - 100k-Party schon geplant

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

NEL ASA-Aktie fällt immer tiefer: Analysten sehen Risiken und raten zum Verkauf

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.11.2024 15:32
Kaufwert:	EUR
	Hinzufügen Speichern